Charles River Laboratories International (NYSE:CRL) Updates FY 2025 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 9.100-9.600 for the period, compared to the consensus earnings per share estimate of 9.600. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion. Charles River Laboratories International also updated its FY25 guidance to $9.10-$9.60 EPS.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research report on Monday, November 18th. Morgan Stanley cut their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Bank of America cut their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Finally, TD Cowen raised their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $195.71.

Charles River Laboratories International Trading Up 0.6 %

Shares of Charles River Laboratories International stock opened at $163.25 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International has a 1 year low of $150.79 and a 1 year high of $275.00. The company has a market capitalization of $8.35 billion, a P/E ratio of 1,088.33, a P/E/G ratio of 6.77 and a beta of 1.37. The business has a 50 day moving average price of $173.39 and a 200 day moving average price of $188.81.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s revenue was down 1.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.46 EPS. Sell-side analysts anticipate that Charles River Laboratories International will post 9.41 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).